3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
323
Fallopian Tube Neoplasms
159
Carcinoma, Ovarian Epithelial
114
Endometrial Neoplasms
77
Uterine Cervical Neoplasms
72
Neoplasms
28
Carcinoma, Non-Small-Cell Lung
24
Breast Neoplasms
23
Brenner Tumor
21
Recurrence
19
Testicular Neoplasms
17
Peritoneal Neoplasms
17
Stomach Neoplasms
14
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
11
Urinary Bladder Neoplasms
10
Testicular Germ Cell Tumor
10
Sarcoma
10
Pancreatic Neoplasms
10
Lung Neoplasms
10
Colorectal Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
9
Teratoma
8
Ovarian Germ Cell Cancer
8
Neuroectodermal Tumors, Primitive, Peripheral
8
Central Nervous System Neoplasms
8
Uterine Neoplasms
7
Small Cell Lung Carcinoma
7
Melanoma
7
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Carboplatin
×
Gynecologic
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled